186 related articles for article (PubMed ID: 38418456)
1. Structure of the p53 degradation complex from HPV16.
Wang JCK; Baddock HT; Mafi A; Foe IT; Bratkowski M; Lin TY; Jensvold ZD; Preciado López M; Stokoe D; Eaton D; Hao Q; Nile AH
Nat Commun; 2024 Feb; 15(1):1842. PubMed ID: 38418456
[TBL] [Abstract][Full Text] [Related]
2. Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.
Conrady MC; Suarez I; Gogl G; Frecot DI; Bonhoure A; Kostmann C; Cousido-Siah A; Mitschler A; Lim J; Masson M; Iftner T; Stubenrauch F; Travé G; Simon C
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115863
[TBL] [Abstract][Full Text] [Related]
3. Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53.
Cooper B; Schneider S; Bohl J; Jiang Yh; Beaudet A; Vande Pol S
Virology; 2003 Feb; 306(1):87-99. PubMed ID: 12620801
[TBL] [Abstract][Full Text] [Related]
4. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
[TBL] [Abstract][Full Text] [Related]
5. Multiple regions of E6AP (UBE3A) contribute to interaction with papillomavirus E6 proteins and the activation of ubiquitin ligase activity.
Drews CM; Brimer N; Vande Pol SB
PLoS Pathog; 2020 Jan; 16(1):e1008295. PubMed ID: 31971989
[TBL] [Abstract][Full Text] [Related]
6. Human Papillomavirus 16 (HPV-16), HPV-18, and HPV-31 E6 Override the Normal Phosphoregulation of E6AP Enzymatic Activity.
Thatte J; Banks L
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835500
[TBL] [Abstract][Full Text] [Related]
7. Peptide interactions stabilize and restructure human papillomavirus type 16 E6 to interact with p53.
Ansari T; Brimer N; Vande Pol SB
J Virol; 2012 Oct; 86(20):11386-91. PubMed ID: 22896608
[TBL] [Abstract][Full Text] [Related]
8. HPV16 E6 induces chromosomal instability due to polar chromosomes caused by E6AP-dependent degradation of the mitotic kinesin CENP-E.
Cosper PF; Hrycyniak LCF; Paracha M; Lee DL; Wan J; Jones K; Bice SA; Nickel K; Mallick S; Taylor AM; Kimple RJ; Lambert PF; Weaver BA
Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2216700120. PubMed ID: 36989302
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the mechanisms of HPV E6 mutations in the destabilization of E6/E6AP/p53 complex.
Li L; Dong X; Tang Y; Lao Z; Li X; Lei J; Wei G
Biophys J; 2022 May; 121(9):1704-1714. PubMed ID: 35364103
[TBL] [Abstract][Full Text] [Related]
10. Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function.
Cherry JJ; Rietz A; Malinkevich A; Liu Y; Xie M; Bartolowits M; Davisson VJ; Baleja JD; Androphy EJ
PLoS One; 2013; 8(12):e84506. PubMed ID: 24376816
[TBL] [Abstract][Full Text] [Related]
11. Stepwise multipolyubiquitination of p53 by the E6AP-E6 ubiquitin ligase complex.
Masuda Y; Saeki Y; Arai N; Kawai H; Kukimoto I; Tanaka K; Masutani C
J Biol Chem; 2019 Oct; 294(41):14860-14875. PubMed ID: 31492752
[TBL] [Abstract][Full Text] [Related]
12. A ubiquitin variant-based affinity approach selectively identifies substrates of the ubiquitin ligase E6AP in complex with HPV-11 E6 or HPV-16 E6.
Ebner FA; Sailer C; Eichbichler D; Jansen J; Sladewska-Marquardt A; Stengel F; Scheffner M
J Biol Chem; 2020 Oct; 295(44):15070-15082. PubMed ID: 32855237
[TBL] [Abstract][Full Text] [Related]
13. Involvement of a cellular ubiquitin-protein ligase E6AP in the ubiquitin-mediated degradation of extensive substrates of high-risk human papillomavirus E6.
Matsumoto Y; Nakagawa S; Yano T; Takizawa S; Nagasaka K; Nakagawa K; Minaguchi T; Wada O; Ooishi H; Matsumoto K; Yasugi T; Kanda T; Huibregtse JM; Taketani Y
J Med Virol; 2006 Apr; 78(4):501-7. PubMed ID: 16482544
[TBL] [Abstract][Full Text] [Related]
14. Association of E6AP (UBE3A) with human papillomavirus type 11 E6 protein.
Brimer N; Lyons C; Vande Pol SB
Virology; 2007 Feb; 358(2):303-10. PubMed ID: 17023019
[TBL] [Abstract][Full Text] [Related]
15. Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.
Stutz C; Reinz E; Honegger A; Bulkescher J; Schweizer J; Zanier K; Travé G; Lohrey C; Hoppe-Seyler K; Hoppe-Seyler F
PLoS One; 2015; 10(7):e0132339. PubMed ID: 26151636
[TBL] [Abstract][Full Text] [Related]
16. Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6.
Lagrange M; Charbonnier S; Orfanoudakis G; Robinson P; Zanier K; Masson M; Lutz Y; Trave G; Weiss E; Deryckere F
J Gen Virol; 2005 Apr; 86(Pt 4):1001-1007. PubMed ID: 15784893
[TBL] [Abstract][Full Text] [Related]
17. Expression of the Long Noncoding RNA DINO in Human Papillomavirus-Positive Cervical Cancer Cells Reactivates the Dormant TP53 Tumor Suppressor through ATM/CHK2 Signaling.
Sharma S; Munger K
mBio; 2020 Jun; 11(3):. PubMed ID: 32546626
[TBL] [Abstract][Full Text] [Related]
18. Felis catus papillomavirus type-2 E6 binds to E6AP, promotes E6AP/p53 binding and enhances p53 proteasomal degradation.
Altamura G; Power K; Martano M; Degli Uberti B; Galiero G; De Luca G; Maiolino P; Borzacchiello G
Sci Rep; 2018 Dec; 8(1):17529. PubMed ID: 30510267
[TBL] [Abstract][Full Text] [Related]
19. Differential localization of HPV16 E6 splice products with E6-associated protein.
Vaeteewoottacharn K; Chamutpong S; Ponglikitmongkol M; Angeletti PC
Virol J; 2005 Jun; 2():50. PubMed ID: 15960845
[TBL] [Abstract][Full Text] [Related]
20. Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6.
Wang H; Mo P; Ren S; Yan C
J Biol Chem; 2010 Apr; 285(17):13201-10. PubMed ID: 20167600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
